Ixabepilone, first in a new class of antineoplastic agents: The natural epothilones and their analogues

Clinical Breast Cancer

Volumn 7, Issue 10, 2007, Pages 9-15

  Fornier, Monica N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antimicrotubule agents; Epothilone B; HER2 neu; tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BEVACIZUMAB; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GLYCOPROTEIN P; IXABEPILONE; KOS 1584; MACROLIDE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTHRALGIA; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO CULTURE; LEUKOPENIA; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; REVIEW; TUMOR RESISTANCE; WEAKNESS;

EID: 36048979369     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.036     Document Type: Review

References (42)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275-292.
2. Kamath K, Wilson L, Cabral F, et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280:12902-12907.
3. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-17125.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
5. Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94:S6 (Abstract #3).
6. Gerth K, Bedorf N, Hofle G, et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49:560-563.
7. Bode CJ, Gupta ML Jr, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41:3870-3874.
8. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-2333.
9. Rojas-Espaillat LA, Uyar D, Grabowski D, et al. Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells. Proc Am Assoc Cancer Res 2005; 46:1257 (Abstract #5318).
10. Yamaguchi H, Chen J, Bhalla K, et al. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004; 279:39431-39437.
11. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Canc Agents 2002; 2:123-148.
12. Jordan MA, Miller H, Ray A, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 2006; 47:(Abstract #LB-280).
13. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-1437.
14. Lee FY, Castenada S, Hawken D, et al. Bevacizumab/ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab/paclitaxel combination. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; November 14-18, 2005; Philadelphia, PA. Abstract #B246.
15. Lee FY, Castaneda S, Inigo I, et al. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2-dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005; 23(16 suppl):19s (Abstract #561).
16. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21:1866-1873.
17. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10:1289-1298.
18. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-2734.
19. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25:3415-3420.
20. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-3406.
21. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407-3414.
22. Baselga J, Gianni L, Llombart A, et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat 2005; 94:S31 (Abstract #305).
23. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 2006; 24(18 suppl):568s (Abstract #10511).
24. Vansteenkiste JF, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25:3448-3455.
25. Hussain M, Tangen CM, Lara PN, Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23:8724-8729.
26. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23:1439-1446.
27. Whitehead RP, McCoy S, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006; 24:515-520.
28. Fojo AT, Menefee ME, Poruchynsky M, et al. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 2005; 23(16 suppl):388s (Abstract #4541).
29. O'Connor O, Straus D, Moskowitz C, et al. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease. J Clin Oncol 2005; 23(16 suppl):577s (Abstract #6569).
30. Smith SM, Pro B, van Besien K, et al. A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. J Clin Oncol 2005; 23(16 suppl):591s (Abstract #6625).
31. Eng C, Kindler HL, Skoog L, et al. The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2003; 22:282 (Abstract #1134).
32. Pavlick AC, Millward M, Farrell K, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC #710428) in stage IV malignant melanoma (MM). Proc Am Soc Clin Oncol 2004; 23:717 (Abstract #7542).
33. Fornier MN, Martin M, Klimovsky J, et al. Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: final report. J Clin Oncol 2006; 24(18 suppl):575s (Abstract #10587)
34. Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol 2007; 25(18 suppl):33s (Abstract #1006).
35. Smit W, Sufliarsky J, Spanik S, et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. J Clin Oncol 2005; 23(16 suppl):468s (Abstract #5056).
36. Thompson J, Swerdloff J, Escudier B, et al. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol 2003; 22:405 (Abstract #1628).
37. Østerlind K, Sánchez JM, Zatloukal P, et al. Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. J Clin Oncol 2005; 23(16 suppl):647s (Abstract #7110).
38. Buzdar A, Silverman P, Kaufman PA, et al. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. Breast Cancer Res Treat 2005; 94:S69 (Abstract #1087).
39. Overmoyer B, Waintraub S, Kaufman P, et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005; 23(16 suppl):72s (Abstract #778).
40. Schmid P, Kiewe P, Kuehnhardt D, et al. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 2005; 23(16 suppl):147s (Abstract #2051).
41. Villalona-Calero M, S Goel, Schaaf L, et al. First-in-human phase I trial of a novel epothilone, KOS-1584. J Clin Oncol 2006; 24(18 suppl):79s (Abstract #2003).
42. Burris H, Stopeck A, Thomas E, et al. Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule. Eur J Cancer Supplements 2006; 4:192 (Abstract #638).